A. HOMBACH ET AL.: "Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.", GENE THERAPY, vol. 17, no. 10, October 2010 (2010-10-01), pages 1206 - 1213, XP002718447 (B1)

WANG L.F. & YU M.: "Epitope identification and discovery using phage display libraries: Applications in vaccine development and diagnostics", CURRENT DRUG TARGETS, vol. 5, 2004, pages 1 - 15 (B1)

A. HOMBACH ET AL.: "Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.", JOURNAL OF IMMUNOTHERAPY, vol. 22, no. 6, November 1999 (1999-11-01), USA, pages 473 - 480, XP001109096 (B1)

ANDREAS A HOMBACH ET AL: "Superior Therapeutic Index in Lymphoma Therapy: CD30+ CD34+ Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack", MOLECULAR THERAPY, vol. 24, no. 8, 1 August 2016 (2016-08-01), GB, pages 1423 - 1434, XP055336226, ISSN: 1525-0016, DOI: 10.1038/mt.2016.82 (B1)

ANDREAS A. HOMBACH ET AL: "Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?", EXPERT REVIEW OF CLINICAL IMMUNOLOGY, vol. 13, no. 2, 21 February 2017 (2017-02-21), GB, pages 151 - 155, XP055414305, ISSN: 1744-666X, DOI: 10.1080/1744666X.2016.1221763 (B1)

B. SAVOLDO ET AL.: "Epstein Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial T-cell receptor for immunotherapy of Hodgkin disease.", BLOOD, vol. 110, no. 7, 1 October 2007 (2007-10-01), USA, pages 2620 - 2630, XP002718444 (B1)

CHENG T.L. & ROFFLER S.: "Membrane-tethered proteins for basic research, imaging and therapy.", MED. RES. REVIEWS, vol. 28, no. 6, 2008, pages 885 - 928 (B1)

CHMIELEWSKI M., HOMBACH A.A. & ABKEN H.: "CD28 cosignaling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack", GENE THER.-, vol. 18, 2011, pages 62 - 72 (B1)

D. KOFLER ET AL.: "CD28 costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing lck activation.", MOLECULAR THERAPY, vol. 19, no. 4, April 2011 (2011-04-01), pages 760 - 767, XP055066111 (B1)

DE-A1- 19 640 733 (B1)

DI STASI A. ET AL.: "T lyphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.", BLOOD, vol. 113, no. 25, 18 June 2009 (2009-06-18), pages 6392 - 6402 (B1)

EDERER C.: "CCR7- T-Zellen benötigen CD28-OX40 Kostimulation für die Immunorezeptor-vermittelte Tumorlyse", April 2009, UNIVERSITÄT ZU KÖLN, article "Inaugural-Dissertation" (B1)

HOMBACH A ET AL.: "T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis", CANCER RES., vol. 61, 2001, pages 1976 - 1982 (B1)

HOMBACH A ET AL.: "Tumor-specific T cell activation by recombinant immunoreceptors: CD3zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3zeta signaling receptor molecule.", J. IMMUNOL.§, vol. 137, 2001, pages 6123 - 6131 (B1)

HOMBACH A. ET AL.: "Superior therapeutic index in lymphoma therapy: CD30+ CD34+ hematopoietic stem cells resist a chimeric antigen receptor T-cell attack", MOL. THER., vol. 24, no. 8, August 2016 (2016-08-01), pages 1423 - 1434 (B1)

HOMBACH A. ET AL.: "T cell activation by recombinant FceR1 gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition.", GENE THERAPY, vol. 7, 2000, pages 1067 - 1075 (B1)

RAMOS C.A. ET AL.: "Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes", J. CLIN. INVEST., vol. 127, no. 9, 2017, pages 3462 - 6471 (B1)

S. RIDDELL & U. PROTZER: "Carving the CAR", GENE THERAPY, vol. 17, 2010, pages 1191 - 1192, XP002718446 (B1)

SCHUBERT P.C. ET AL.: "Treatment of malignant pleural mesothelioma by fibroblast acrtivation protein-specific re-directed T cells.", J. TRANSL. MED., vol. 11, 187, 2013 (B1)

A. HOMBACH ET AL.: "An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.", CANCER RESEARCH, vol. 58, no. 6, 15 March 1998 (1998-03-15), USA, pages 1116 - 1119, XP002718445 (B1)